Harga 2 Obat Rekomendasi Terbaru WHO untuk Pasien Covid-19, Tembus Jutaan Rupiah

Any Hidayati

Editor:

  • WHO merekomendasikan Actemra dan Kevzara untuk obat Covid-19.
  • Actemra dibandrol dengan harga Rp1.162.200 dan Rp5.710.600 tergantung dosis.
  • Kevzara belum resmi masuk Indonesia tapi di AS dipatok dengan harga sekitar Rp55 juta untuk dosis 150mg/1,14ml.

SKOR.id - Selasa (6/7/2021), Badan Kesehatan Dunia (WHO) merekomendasikan dua jenis obat radang sendi untuk pengobatan Covid-19.

Dilansir dari Reuters.com, obat yang dimaksud oleh WHO tersebut adalah Actemra dari Roche dan Kevzara dari Sanofi.

Kedua obat tersebut telah diuji WHO kepada 10.930 pasien Covid-19 kategori berat dan kritis yang mana pasien yang mendapat suntikan salah satu obat tersebut memiliki progres positif ketimbang yang hanya mendapat perawatan biasa.

Sebanyak 6.449 orang menggunakan salah satu obat radang sendi tersebut memiliki kemungkinan hidup lebih besar dari 4.481 orang lainnya hanya mendapat perawatan biasa selama 28 hari pengujian tersebut.

Dilansir dari Kompas.com, obat jenis Acterma dapat mengatasi badai sitokin atau respon berlebihan tubuh terhadap infeksi ketika terpapar Covid-19.

Sehingga kerusakan organ tubuh akibat badai sitokin saat terpapar Covid-19 dapat ditekan karena menurunkan beberapa penanda inflamasi atau peradangan.

Meskipun telah teruji klinis, Actemra dan Kevzara adalah obat radang sendi yang tergolong obat keras.

Sehingga obat tersebut harus mendapat pengawasan ketat dari dokter atau tenaga kesehatan selama proses pemulihan.

Badan pengawas obat dan makanan Amerika Serikat telah memberikan izin edar untuk dua jenis obat tersebut sejak pekan lalu.

Di Indonesia, baru Actemra yang telah resmi beredar di pasaran dan mendapat izin edar dari Badan Pengawas Obat dan Makanan (BPOM).

Actemra atau Tocilizumab dosis 400mg/20ml dijual dengan harga Rp5.710.600. Sedangkan, dosis 80mg/4ml dibandrol dengan harga Rp1.162.200.

Kevzara di Amerika Serikat dipatok dengan harga 3.827 dolar AS atau setara Rp55 juta untuk dosis 150mg/1,14ml.

Walaupun telah direkomendasikan oleh WHO, dua obat radang sendi tersebut mempunyai beberapa efek samping untuk pemakainya.

Dilansir dari KATADATA Indonesia, kedua obat tersebut memiliki efek samping antara lain, infeksi pernapasan, sakit kepala, tekanan darah tinggi, peningkatan enzim hati, dan alergi.

Ikuti juga InstagramFacebookYouTube, dan Twitter dari Skor Indonesia.

Berita Covid-19 Lainnya:

Mengenal Perbedaan Sinovac dan AstraZeneca, 2 Vaksin yang Dipakai di Indonesia

Catat, Hal yang Perlu Diperhatikan Sebelum dan Setelah Vaksinasi Covid-19

Source: KompasReutersKata Data

RELATED STORIES

5 Bintang NBA yang Gagal Lolos ke Olimpiade Tokyo, 2 MVP Jadi Korban

5 Bintang NBA yang Gagal Lolos ke Olimpiade Tokyo, 2 MVP Jadi Korban

Ada beberapa pemain asing NBA yang berstatus bintang namun absen di Olimpiade 2020 Tokyo karena negaranya tak lolos

3 Rekomendasi Olahraga saat Isolasi Mandiri dengan Gejala Ringan Covid-19

Demi menjaga diri dan lingkungan sekitar, masyarakat yang mengalami gejala ringan-sedang Covid-19 disarankan untuk melakukan isolasi mandiri.

Skor co creators network
RIGHT_ARROW
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
RIGHT_ARROW

THE LATEST

Piala AFF U-23 2025 atau ASEAN U-23 Championship 2025. (Deni Sulaeman/Skor.id)

Timnas Indonesia

Piala AFF U-23 2025: Jadwal, Hasil dan Klasemen Lengkap

Jadwal, hasil, dan klasemen ASEAN U-23 Championship 2025, yang terus diperbarui seiring berjalannya turnamen.

Taufani Rahmanda | 21 Jul, 16:39

Basket 3x3

Basketball

FIBA 3X3 Jakarta 2025, Indonesia Pasang Target Besar Menuju Olimpiade 2028

Dua ajang internasional, FIBA 3X3 Women’s Series Jakarta 2025 dan FIBA 3X3 Challenger Jakarta 2025, siap digelar berturut-turut.

Nizar Galang | 21 Jul, 16:37

EVOS Rasyah MVP Free Fire di Esports World Cup 2025. (Garena)

Esports

MVP di Free Fire Esports World Cup 2025, Ini Statistik EVOS Rasyah

Rasyah mampu mengantarkan EVOS Divine meraih trofi di ajang Esports World Cup 2025.

Gangga Basudewa | 21 Jul, 15:11

Bloodthirsty King gabung Honor of Kings. (Grafis: Deni Sulaeman/Skor.id)

Esports

BTK dan Mobazane Resmi Gabung Honor of Kings

MobaZane dkk diumumkan bergabung dengan skena Honor of Kings mewakili region North America.

Gangga Basudewa | 21 Jul, 13:15

EVOS Divine Juara EWC 2025 Free Fire. (Garena)

Esports

Juara Free Fire di Esports World Cup 2025, Ini Kata Kapten EVOS Divine

EVOS Divine mengukir sejarah dengan menjadi tim Indonesia pertama yang menjadi juara dunia di Grand Final Esports World Cup: Free Fire 2025.

Gangga Basudewa | 21 Jul, 12:04

Lanny Tria Mayasari/Siti Fadia Silva Ramadhanti

Badminton

Lanny/Fadia Mundur dari China Open 2025

Lanny Tria Mayasari/Siti Fadia Silva Ramadhanti ditarik keikusertaannya dari ajang Cina Open 2025 karena Fadia mengalami sakit.

Gangga Basudewa | 21 Jul, 10:51

hector souto - timnas futsal indo

Futsal

Ikuti Turnamen di Cina, Hector Souto Ingin Lihat Sejauh Mana Potensi Timnas Futsal Indonesia

Hector Souto memanggil 19 pemain untuk mengikuti TC persiapan turnamen di Cina, September nanti.

Rais Adnan | 21 Jul, 10:32

TopSkor Indonesia.

Liga TopSkor

Tampil Dominan di Persija Future Cup 2025, TSI Jakarta Kalahkan Akademi Persib Bandung

TSI Jakarta U-15 mengawali kiprahnya di Persija Future Cup 2025 dengan meraih poin penuh, Senin (1/7/2025).

Nizar Galang | 21 Jul, 10:07

Gustavo Franca Amadio (Persija Jakarta. (Foto: Dok. Persija/Grafis: Deni Sulaeman/Skor.id)

Liga 1

Resmi Gabung Persija, Gustavo Franca Janjikan Cetak Gol dan Assist

Gustavo Franca resmi diumumkan sebagai pemain asing keenam Persija untuk musim 2025-2026.

Rais Adnan | 21 Jul, 10:05

Timnas futsal Indonesia. (Foto: Media FFI/Grafis: Yusuf/Skor.id)

Futsal

Timnas Futsal Indonesia Didominasi Nama-nama Baru untuk Persiapan Turnamen di Cina

FFI mengumumkan 19 pemain untuk TC Timnas futsal Indonesia menuju CFA International Men's Futsal Tournament.

Taufani Rahmanda | 21 Jul, 09:44

Load More Articles